Armata Pharmaceuticals, Inc. (ARMP)
NYSEAMERICAN: ARMP · Real-Time Price · USD
3.670
+0.080 (2.23%)
Sep 30, 2026, 4:00 PM EDT - Market closed
Armata Pharmaceuticals Revenue
Armata Pharmaceuticals had revenue of $2.51M in the quarter ending June 30, 2026, with 15.72% growth. This brings the company's revenue in the last twelve months to $5.54M, down -19.29% year-over-year. In the year 2025, Armata Pharmaceuticals had annual revenue of $4.90M, down -5.22%.
Revenue (ttm)
$5.54M
Revenue Growth
-19.29%
P/S Ratio
24.62
Revenue / Employee
$90,869
Employees
61
Market Cap
136.46M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.90M | -270.00K | -5.22% |
| Dec 31, 2024 | 5.17M | 645.00K | 14.24% |
| Dec 31, 2023 | 4.53M | -979.00K | -17.77% |
| Dec 31, 2022 | 5.51M | 1.03M | 23.11% |
| Dec 31, 2021 | 4.47M | 3.65M | 443.62% |
| Dec 31, 2020 | 823.00K | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | 115.00K | -145.00K | -55.77% |
| Dec 31, 2016 | 260.00K | -215.00K | -45.26% |
| Dec 31, 2015 | 475.00K | 66.00K | 16.14% |
| Dec 31, 2014 | 409.00K | 328.00K | 404.94% |
| Dec 31, 2013 | 81.00K | -583.00K | -87.80% |
| Dec 31, 2012 | 664.00K | -8.05M | -92.38% |
| Dec 31, 2008 | 8.72M | -1.61M | -15.62% |
| Dec 31, 2007 | 10.33M | 468.00K | 4.74% |
| Dec 31, 2006 | 9.86M | 2.99M | 43.50% |
| Dec 31, 2005 | 6.87M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Codexis | 77.68M |
| Atrium Therapeutics | 35.84M |
| Caribou Biosciences | 10.04M |
| Korro Bio | 2.38M |
| Kazia Therapeutics | 1.27M |
| Spruce Biosciences | 697.00K |
ARMP News
- 7 days ago - Armata Pharmaceuticals receives $3.7M in additional funding from DoW - TheFly
- 7 days ago - Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development - PRNewsWire
- 9 days ago - Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates - PRNewsWire
- 16 days ago - Armata Pharmaceuticals receives FDA Breakthrough Therapy Designation for AP-SA02 - TheFly
- 16 days ago - Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02 - PRNewsWire
- 20 days ago - Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - PRNewsWire
- 27 days ago - Armata Pharmaceuticals announces new published paper on Ar-KM - TheFly
- 27 days ago - Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials - PRNewsWire